A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID)
Titel:
A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID)
Auteur:
Viallard, J.-F. Brion, J.-P. Malphettes, M. Durieu, I. Gardembas, M. Schleinitz, N. Hoarau, C. Lazaro, E. Puget, S.
Verschenen in:
Revue de medecine interne
Paginering:
Jaargang 38 (2017) nr. 9 pagina's 7 p.
Jaar:
2017
Inhoud:
Uitgever:
Société Nationale Française de Médecine Interne (SNFMI)